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Objective: To review MRI findings of pure lobular neoplasia (LN) on MRI guided biopsy, evaluate surgical and
clinical outcomes, and assess imaging findings predictive of upgrade to malignancy.
Methods: HIPAA compliant, IRB-approved retrospective review of our MRI-guided breast biopsy database from
October 2008–January 2015. Biopsies yielding atypical lobular hyperplasia or lobular carcinoma in situ were
included in the analysis; all biopsy slides were reviewed by a dedicated breast pathologist. Imaging indications,
MRI findings, and histopathology were reviewed. Statistical analysis was performed using the two-tailed Fisher
exact-test and the t-test, and 95% CIs were determined. A p < 0.05 was considered statistically significant.
Results: Database search yielded 943 biopsies in 785 patients of which 65/943 (6.9%) reported LN as the highest
risk pathologic lesion. Of 65 cases, 32 were found to have LN as the dominant finding on pathology and
constituted the study population. All 32 findings were mammographically and sonographically occult. Three of
32 (9.3%) cases of lobular neoplasia were upgraded to malignancy, all LCIS (one pleomorphic and two classical).
The most common MRI finding was focal, heterogenous non-mass enhancement with low T2 signal. No clinical
features or imaging findings were predictive of upgrade to malignancy.
Conclusion: Incidence of pure lobular neoplasia on MRI guided biopsy is low, with comparatively low incidence of
upgrade to malignancy. No imaging or clinical features are predictive of upgrade on surgical excision, therefore,
prudent radiologic-pathologic correlation is necessary.

1. Introduction
First described by Ewing in 1919 and further defined by Foote and
Steward in 1941, lobular neoplasia (LN) is defined as a spectrum of
atypical epithelial proliferations that originate in the terminal ductal
lobular unit (TDLU) [1,2]. LN includes both lobular carcinoma in situ
(LCIS) and atypical lobular hyperplasia (ALH), and is described as small,
non-cohesive cells that expand the acini [1]. LCIS is histologically
distinguished from ALH by distention of more than half of the acini of
the lobule by neoplastic cells; ALH falls short of this diagnostic
threshold. In addition, the loss of membranous expression of E-cadherin,
a transmembrane protein encoded by the CDH1 gene on chromosome 16
and involved in intercellular adhesion, is characteristic of LN and can

help distinguish it from ductal carcinoma in situ (DCIS) [1].
Women with a prior diagnosis of LN have an increased risk of breast
cancer [2,3]. In women with history of lobular carcinoma in situ (LCIS),
there is an 8–10 fold increased risk of breast cancer [2], with an
approximately 1% per year likelihood of developing intraductal or
invasive breast cancer [4]. Studies have shown that women with a prior
diagnosis of ALH, who did not receive chemoprevention for breast
cancer, had a 20.7% 10-year risk of breast cancer [5,6]. Of note, LN is
considered both a risk factor for breast cancer and nonobligate precursor
of invasive breast cancer [7,8].
The true incidence of LN is unknown but has been reported as
approximately 0.5–3.8% of benign breast biopsies and the finding is
usually incidental [9,10]. When identified as an imaging target, it most
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often presents as suspicious microcalcifications on mammography
[11,12]. The imaging appearance of LN on ultrasound and breast MRI is
less well defined. A recent study by Ferre et al. described 22 cases of LN
diagnosed on ultrasound-guided biopsy and found no distinctive imag
ing appearance of LN, nor any clinical or imaging characteristics pre
dictive of malignancy [13]. At this time, only one systematic review of
LN on breast MRI has been reported in the pathology literature and it is
uncertain as to what imaging findings on MRI can be attributed to LN
[14]. Given the variability that exists in the management of lobular
neoplasia, it is important to be certain of radiology and pathology
concordance. The goal of this study was to review the MRI findings of
lobular neoplasia detected on MRI guided biopsy, report the incidence of
upgrade to cancer, and identify imaging findings predictive of
malignancy.

GE 3 T HDX (General Electric Medical Systems, Milwaukee, WI), or a
Siemens Trio 3 T (Siemens Medical, NC) scanner, using a dedicated
breast surface coil (16-channel Siemens, 8-channel GE, or 7-channel
InVivo [Orlando, FL]). Sequences included a three-plane localizing
sequence, axial fat-suppressed T2-weighted (T2W) fast spin- echo or T2
STIR sequence, and axial fast spoiled gradient T1W non–fat-suppressed
sequence before contrast administration. After 2010, dynamic T1W fatsuppressed 3D fast spoiled gradient echo (3D FSPGR) sequences are then
performed before and four times after intravenous administration of
contrast (0.1 mmol/kg, Magnevist; Berlex, NJ) in the axial plane. A T1W
3D FSPGR delayed postcontrast sequence is acquired in the sagittal
plane. Before 2010, dynamic images were acquired in either the sagittal
or the axial plane, with delayed imaging performed in the orthogonal
plane. Postprocessing, including subtraction axial images, maximum
intensity projections (MIP), and computer aided diagnosis (CAD
STREAM or iCAD), is routinely used.
Our biopsy technique includes non-contrast axial and sagittal T1weighted fat-saturated 3D spoiled gradient-recalled echo sequences
(VIBRANT, GE Healthcare) was first performed to identify the target in
grid. After IV administration of gadolinium dimeglumine (Magnevist,
Bayer HealthCare) was performed, an MRI-compatible coaxial 9-gauge
vacuum-assisted biopsy system was used to obtain 20-mm (standard)
or 12-mm (petite) core specimens (ATEC console, handpieces, and
disposable introducer sets, Suros Surgical Systems, Hologic). An ATEC
TriMark biopsy marker (Suros Surgical Systems, Hologic) was deployed
after ensuring satisfactory tissue sampling. Postprocedure orthogonal
mammographic views were obtained to ensure appropriate clip
placement.

2. Materials and methods
A HIPAA compliant, IRB-approved retrospective review was per
formed of our institution’s MRI-guided breast biopsy database from
October 1, 2008 to January 1, 2015. During this time 943 MRI-guided
breast biopsies were performed on 785 patients.
2.1. Inclusion criteria and pathology review
Pathology reports of all the biopsies were reviewed by one of two
authors (SAC, ECG) and 65/943 (6.9%) biopsies revealed lobular
neoplasia as the highest risk pathologic lesion at MRI-guided core needle
biopsy. All 65 cases were then reviewed by a pathologist with expertise
in breast disease (BTH) to confirm the diagnosis of LN, to determine that
it was the most significant pathology and to evaluate the presence of
benign entities within the core specimen. Lobular neoplasia was classi
fied as ALH, classic LCIS or pleomorphic LCIS according to the most
recent criteria by the World Health Organization. Classic LCIS and ALH
are characterized by a low-to-intermediate grade proliferation of
monomorphic, poorly cohesive neoplastic epithelial cells, with LCIS
filling and distending >50% of the acini of a lobule and ALH falling short
of this. Pleomorphic LCIS is a morphologic variant of LCIS composed of
larger cells with marked nuclear pleomorphism, which are >4 times the
size of a lymphocyte (equivalent to high-grade DCIS), with or without
apocrine features. Pleomorphic LCIS often displays a florid and expan
sile growth pattern with central comedo-type necrosis. Additional fea
tures of the LN were evaluated, including the greatest linear extent of
involvement of tissue core, growth pattern (pagetoid, solid or florid),
distribution (nodular, clustered, dispersed or focal) and focality(focal: 1
focus, multifocal: 2–10 foci, or extensive: > 10 foci). Upon pathology
review, LN lesions associated with benign entities such as papillomas or
fibroadenomas, which likely represented the targeted radiologic lesion,
were excluded. The LN lesions associated with concomitant flat
epithelial atypia, atypical ductal hyperplasia (ADH), or malignancy
(ductal carcinoma in situ [DCIS], invasive ductal carcinoma [IDC],
invasive lobular carcinoma [ILC]) were also excluded. Pure LN was
defined as LN without any concomitant atypia. At time of original bi
opsy, potentially discordant results were prospectively discussed at a
routine biweekly radiology-pathology conference. The standard practice
at our institution was to recommend excision for any histopathologic
result believed to be discordant with the level of suspicion based on
initial imaging. At our institution, surgical excision is recommended for
atypical ductal hyperplasia, radial scar, complex sclerosing lesions,
papillomas with atypia and fibroepithelial lesions. LN does not routinely
undergo surgical excision at our institution, however, the final decision
is at the discretion of the surgeon and patient.

2.3. Imaging and medical record review
All available imaging of the 65 cases were reviewed including
mammography, ultrasound, breast MRI examinations and subsequent
MRI-guided biopsies in consensus by two breast fellowship trained ra
diologists with 5 and 20 years of experience in breast imaging (XX, XX).
Those cases where the breast pathologist or radiologists believed other
pathologies could account for the MRI imaging findings were excluded
from analysis. The MRI imaging characteristics were evaluated accord
ing to the 5th edition of the BI-RADS lexicon [15], including fibro
glandular tissue amount, background parenchymal enhancement,
morphology (mass, nonmass, focus), T2 intensity compared to the signal
intensity of normal breast parenchyma, and kinetics. Of note, no cases of
MRI detected LN had an ultrasound or mammographic correlate.
MRI reports were retrospectively reviewed for study indication and
original prospective breast imaging reporting and data system (BIRADS) assessment. The electronic medical record was reviewed to
obtain patient demographics including study indication, age at biopsy,
biopsy and surgical histopathology, personal history of breast cancer or
prior high-risk lesion, BRCA status, history of thoracic radiation, and any
family history of breast cancer in a first-degree relative. BI-RADS as
signments were prospectively assigned per the BI-RADS MRI lexicon.
2.4. Statistical analysis
Statistical analysis was performed using the two-tailed Fisher exacttest and the t-test, and 95% CIs were determined. A p < 0.05 was
considered statistically significant. Data analysis was performed using
commercially available statistical software (SAS, version 9.2, SAS
Institute).
3. Results

2.2. Breast MRI and MRI biopsy techniques

3.1. Study population

Breast MRI technique at our institution during the study interval
included prone unilateral or bilateral imaging on either a GE Signa 1.5 T,

Sixty-five biopsies in 63 women resulted in pathology findings of LN
during the study period. The overall incidence of lobular neoplasia on
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breast MRI-guided biopsies was 65/943 (6.9%). Of these 65 biopsies, 12
(12/65, 18.5%) cases were excluded because pathology slides were not
available for review. Of the remaining 53 cases, 21 (21/53, 39.6%) were
excluded because on consensus imaging and pathology review, a lesion
other than LN was best considered the dominant correlative imaging and
pathology feature: cluster of cysts (n = 6), papilloma (n = 4), fibroa
denoma/fibroadenomatoid changes (n = 3), PASH (n = 3), radial scle
rosing lesion (n = 2), fat necrosis (n = 1), silicone mastitis (n = 1), and
stromal fibrosis (n = 1). Therefore, 32 cases in 32 patients constitute the
study population; the average age was 53.1 years, range 39–76 years
old. The incidence of pure LN on breast MRI-guided biopsies was 32/943
(3.4%). Of the 32 cases of pure LN, 19/32 (59.4%) were ALH, 8/32
(25%) were LCIS and 5/32 (15.6%) were non-classical LCIS (all
pleomorphic).

Table 2
Imaging Features of Pure LN (n = 32)
Feature
Morphology
Mass (n = 11)
Non-mass (n = 17)
Focus (n = 4)
Mass Shape (n = 11)
Round (n = 1)
Oval (n = 5)
Irregular (n = 5)
Mass margins (n = 11)
Circumscribed (n = 5)
Non-circumscribed (n = 6)
Non-mass distribution (n = 17)
Focal (n = 10)
Linear (n = 2)
Segmental (n = 4)
Regional (n = 1)
Diffuse (n = 0)
Non-mass internal enhancement pattern (n = 17)
Homogeneous (n = 2)
Heterogeneous (n = 11)
Clumped (n = 3)
Clustered ring (n = 1)
T2 intensity (n = 32)
High (n = 4)
Low(n = 28)
LN = Lobular neoplasia

3.2. Clinical factors
The indications for the breast MRI examinations included screening
(13/32, 40.6%) and diagnostic (19/32, 59.4%), including 12 extent of
disease work-ups after recent diagnosis of breast cancer, 4 six-month
follow-up examinations (BI-RADS 3, “probably benign”), 2 MRI exami
nations performed for unknown primary carcinoma, and 1 problem
solving for breast pain (Table 1). Nineteen patients (19/32, 59.4%) were
premenopausal and the remaining 13 (13/32, 40.6%) were post
menopausal. Of the 32 patients, 21 (65.6%) had history of breast cancer
(four had a remote history of breast cancer and 17 with current history
of breast cancer at time of biopsy) and 11/32 (34.4%) had no prior
history of breast cancer. Six patients (6/32, 18.8%) had a prior history of
high-risk lesion, all lobular neoplasia. No clinical factors in patients with
MRI-detected LN were significantly predictive of malignancy upgrade
(Table 1).

All 32 (100%) MRI detected LN were mammographically and sono
graphically occult. Background parenchymal enhancement was minimal
in 9/32 (28.1%) cases, mild in 9/32 (28.1%) cases, moderate in 11/32
(34.4%) cases, and marked in 3/32 (9.4%) cases. The morphology of the
32 cases included 11/32 (34.4%) masses (average size 13.2 mm, range
6–45), 17/32 (53.1%) non-mass enhancement (average size 13.8 mm,
range 7–42), and 4/32 (12.5%) foci.
Of the 11 masses, there were no distinguishing features including
shape, margins, and internal enhancement of pure LN (Table 2). Most
findings had low internal T2 signal intensity (20/32). No imaging fea
tures were significantly predictive of malignancy upgrade.

Morphology
Mass
Non-mass
Focus
Mass shape
Round
Oval
Irregular
Non-mass
distribution
Focal
Linear
Segmental
Regional
Diffuse
Non-mass internal
enhancement
pattern
Homogeneous
Heterogeneous
Clumped
Clustered ring

Table 1
Clinical characteristics of Pure Lobular Neoplasia (LN) Cases (n = 32)
P-value
No

MRI indication
Screening (n = 13)
Diagnostic (n = 19)

2
1

11
18

0.55

History of breast cancer
Yes (n = 21)
No (n = 11)

1
2

20
9

0.26

History of lobular neoplasia
Yes (n = 6)
No (n = 26)

2
1

4
25

0.08

No

0
3
0

11
14
4

0
0
0

1
5
5

0
0

5
6

1
0
1
1
0

9
2
3
0
0

0
2
1
0

2
9
2
1

0
3

4
25

0.36

1.0

1.0

0.15

1.0

1.0

Table 3
Imaging features by histopathology

3.4.1. Atypical lobular hyperplasia
When assessing imaging features by histopathology, the most

Yes

Yes

3.4.2. Lobular carcinoma in situ
There was a total of 13 cases of LCIS, of which 8 were classical LCIS

3.4. Imaging features by histopathology

Upgrade

P-value

common imaging feature of ALH (n = 19) was nonmass enhancement
(11/19, 57.8%), followed by mass (5/19, 26.3%), and focus (3/19,
15.9%) (Table 3). All three foci demonstrated fast initial and delayed
wash-out kinetics. The NME distributions of ALH presenting as NME
were 9/11 (81.8%) focal [8 heterogeneous and 1 homogenous internal
enhancement] and 2/11 (18.2%) linear, both with clumped internal
enhancement. Of the masses, shape was oval (4/5, 80%) or round (1/5,
20%), all with circumscribed margins. No cases of ALH were upgraded
to malignancy on follow up imaging or surgical excision.

3.3. Imaging features of LN

Characteristics

Upgrade

LN = Lobular neoplasia.

Atypical Lobular
Hyperplasia (n =
19)

Classical Lobular
Carcinoma In
Situ (n = 8)

Non-classical
Lobular
Carcinoma in Situ
(n = 5)

5
11
3
n=5
4
1
0
n = 11

3
4
1
n=3
0
0
3
n=4

3
2
0
n=3
0
2
1
n=2

9
1
0
0
0
n = 11

0
0
3
1
0
n=4

1
0
1
0
0
n=2

1
8
2
0

0
2
2
0

0
2
0
0
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malignant on follow up surgical excision or imaging. Al cases of ma
lignancy had extensive LN on initial core biopsy pathology.
Of the three cases upgraded to malignancy (DCIS), all (100%) were
diagnosed as LCIS on core needle biopsy, two (66.7%) with classical
features and one (33.3%) with non-classical pleomorphic features
(Table 3). All malignant cases were non-mass enhancement but with
different distributions (segmental, focal, and regional [Figs. 1]) and
enhancement patterns (two with heterogeneous and one with clumped).
Five cases were non-classical pleomorphic LCIS on pathology review;
1/5 (20%) were upgraded to malignancy of DCIS. The remaining four
(80%) cases of pleomorphic LCIS underwent surgical excision and were
all benign without atypia on final pathology. If cases of pleomorphic
LCIS are removed from analysis, the incidence of malignancy is 2/27
(7.4%).

(61.5%) and the remaining 5 (38.5%) were non-classical, all pleomor
phic variant.
Of the 8 cases of LCIS (classical), four (50%) were NME, three
(37.5%) were masses, and the remaining was a focus (12.5%), which
demonstrated fast initial and delayed wash-out kinetics. The distribution
of NME were 3/4 (75%) segmental, with two heterogeneous and one
clumped internal enhancement; the remaining LCIS-NOS (1/4, 25%)
presenting as NME was regional clumped enhancement. All three masses
were irregular shaped with irregular margins. Two of 8 (25%) LCIS-NOS
were upgraded to malignancy, both presenting as NME (Table 4).
The imaging features of the 5 pleomorphic LCIS were three (60%)
masses which were oval (n = 2) and irregular (n = 1), and two (2/5,
40%) NME. The distribution of the two NME was one segmental and one
focal, both with heterogeneous internal enhancement. One of 5 (20%)
pleomorphic LCIS upgraded to malignancy, also presenting as NME
(Table 3).
There were no distinguishing features to differentiate ALH, LCIS, or
pleomorphic LCIS by shape, margins, or internal enhancement.

4. Discussion
In this retrospective review of our institution’s MRI-guided breast
biopsies, we found that the incidence of pure LN on breast MRI-guided
biopsies was low at 32/943 (3.4%); the overall rate of lobular
neoplasia was 65/943 = 6.9%. The overall upgrade rate to malignancy
of pure LN was 9.3% (3/32), of which all subsequent pathologies were
ductal carcinoma in situ. Finally, we found that pure LN more commonly
presents as non-mass enhancement and tends to be T2 hypointense.
There were no distinguishing MRI imaging features indicative of ma
lignancy upgrade after MRI-guided core needle biopsy.
The diagnosis of lobular neoplasia at MRI-guided core needle biopsy
is variable when compared to other atypical or high-risk lesions [16–18]
. More importantly, few studies delineate pure LN vs mixed LN with
other high-risk histological findings. Our study showed a 3.4% incidence
of pure lobular neoplasia on MRI guided biopsy, similar to that of
Khoury et al. whose rate was 2.1% (34/1655) incidence of LN [14],
which excluded other high-risk lesions such as ADH, papilloma, radial
scar, or flat epithelial atypia. Lourenco, et al., who studied 446 MRIguided biopsies, found similarly low rates of LN with 9/446 (2% inci
dence of LN in total MRI biopsies) as well as both Heller et al. and Strigel
et al. who found rates of 1.8% (6/482) and 3.9% (45/1145) respectively
[19–21]. A more recent study by Speer et al. in 2018 found a slightly
higher rate of 36 cases of lobular neoplasia in all MRI guided biopsies
(425 lesions), for an overall incidence rate of 8.5% [18], which is more
similar to our overall rate of lobular neoplasia (65/943, 6.9%). The
published rates of LN on MRI guided biopsy are more similar to ste
reotactic biopsy (0.9–3.6%) [12,22] but higher than sonographically
detected LN (0.23–1.5%) [13,23,24].
The literature describing imaging MRI features of LN is limited, as LN
is most commonly detected as an incidental finding on core needle bi
opsy [11]. Our study found that the most common morphology of pure
LN was non-mass enhancement (17/32, 53%), which is similar to that of
Ferre et al., who described 10/14 (71.2%) cases of NME and Khoury
et al. who found 22/34 (64.7%) cases of pure LN as NME [13,14]. To our
knowledge, we are the first to report additional MRI imaging features of
pure LN. In our study, the most common NME distribution was focal

3.5. Pathology findings
An average of 8.2 tissue samples was obtained (range 6–12). Histo
pathologic review demonstrated LN as the dominant pathologic finding
in the 32 cases (19/32 (59.4%) ALH, 8/32 (25%) classical LCIS and 5/32
(15.6%) non-classical LCIS, all pleomorphic. Most cases were associated
with additional benign pathology, the majority with more than one
pathology, including columnar cell change (12/32, 37.5%), apocrine
cysts (n = 12/32, 37.5%), benign cysts (n = 11/32, 34.3%), epithelial
hyperplasia (n = 10/32, 31.3%), adenosis (n = 8/32, 25%), pseu
doangiomatous stromal hyperplasia (n = 4/32,12.5%), and fibroade
nomatoid change (n = 2/32, 6.3%). The extent of the LN included focal
(8/32, 25%), multi-focal (12/32, 37.5%), or extensive (12/32, 37.5%).
The distribution of the LN within the tissue was dispersed (22/32,
68.8%), focal (7/32, 21.9%), nodular (2/32, 6.3%), or clustered (1/32,
3.0%). The growth pattern was pagetoid (24/32, 75%), solid (6/
32,18.7%), or florid (2/32, 6.3%). Specific pathologic features did not
correlate with any distinguishing MRI findings.
3.6. Imaging and surgical follow-up
Of the 32 cases of LN, 17/32 (53.2%) cases were followed with MRI
with no evidence of disease to date (range of follow-up 2.3 to 11.0 years,
reviewed to 7/3/2020). Four (4/32, 12.5%) underwent prophylactic
mastectomy of which all were benign on subsequent pathology. The
remaining eleven (11/32, 34.3%) cases were surgically sampled due to
discordance (6/11, 54.4%) or presence of pleomorphic LCIS (5/11,
45.6%). Three (3/11, 27.3%) upgraded to ductal carcinoma in situ
(DCIS) whereas the remaining seven (7/11, 72.7%) were benign without
atypia. Therefore, 3/32 (9.3%) cases of pure lobular neoplasia were
upgraded to malignancy (DCIS) on subsequent pathology in our study.
When all lobular neoplasia is included in the analysis, 3/65 (4.6%) were
upgraded to malignancy on subsequent pathology. No cases of ALH were
Table 4
Clinical, radiological and pathology features of upgrades (n = 3)
Case
#

Age

Menopausal

History of breast
cancer

History of lobular
neoplasia

Core
histology

Excision

MRI
finding

Distribution

Internal
enhancement

T2
intensity

Size

1

56

Post

No

No

LCIS-NOS

DCIS

NME

Regional

Clumped

Low

2
3

51
47

Pre
Pre

No
Yes

No
Yes

LCIS-NOS
LCIS-NC

DCIS
DCIS

NME
NME

Focal
Segmental

Heterogeneous
Heterogeneous

Low
Low

22
mm
7 mm
11
mm

LCIS-NOS: Lobular carcinoma in situ, not otherwise specified (classical).
LCIS-NC: Lobular carcinoma in situ, non-classical.
DCIS: Ductal carcinoma in situ.
NME: Nonmass enhancement.
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Fig. 1. 56-year-old female with history of right atypical lobular hyperplasia for screening breast MRI. Regional clumped non-mass enhancement is present in the
right upper outer breast on axial (1A) and sagittal (1B) planes. MRI-guided core needle biopsy (1C) revealed lobular carcinoma in situ with classical features.
Bracketed MRI-guided wire localization and excision was performed, with final pathology revealing ductal carcinoma in situ, intermediate grade, with necrosis and
extensive lobular carcinoma in situ. The biopsy contained multiple nodular foci of LCIS involving adenosis (1D). The lesion displayed classic cytomorphology with
small, uniform neoplastic cells filing and distending the acini of the terminal duct lobular unit (1E).
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Fig. 1. (continued).

(10/17) and lesions tended to be T2 hypointense (28/32, 87.5%).
Although LN was the most predominant pathology finding in the study
population, cases did include an additional pathology including
columnar cell change and apocrine cysts, contributing to the

heterogeneous MRI imaging appearance. Similar to that described by
Ferre et al. in sonographic LN, the heterogeneity of MRI findings likely
reflects the associated benign pathologies found with lobular neoplasia
[13].
176
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There is ongoing discussion on the management of classical lobular
neoplasia and the surgical and clinical management is often institution
dependent [10,25]. Management guidelines include surgical excision
versus imaging surveillance, depending on the imaging feature and
modality [10,25]. The lack of unified recommendations likely reflects
the wide range of published incidences of malignancy, the heterogeneity
of lobular neoplasia with and without additional high-risk lesions on
pathology, and the lack of radiological and clinical findings that predict
risk of upgrade.
We found that 3/32 (9.3%) of pure LN on our MRI guided biopsies
were upgraded, which is less than that reported by Khoury et al. of 32%
(11/34) [14]. All cases that upgraded were extensive LCIS, two classical
and one pleomorphic, reflecting an upgrade rate of 0% (0/19) for ALH,
25%(2/8) for classical LCIS and 20% (1/5) for pleomorphic LCIS. Our
upgrade rate falls within the published literature range of 0–50%,
however, published rates are based on small sample sizes [10,21]. In the
literature, upgrade rates of ALH range from 0 to 67% (reported mean
9%) and classical LCIS ranges from 5 to 60% (reported mean 18%) [10].
Pleomorphic LCIS, of which we had 5 cases, is routinely managed with
surgical excision; our incidence of malignancy after excision of pleo
morphic LCIS was 20% (1/5), confirming the need for surgical excision.
Given similar upgrade rate of classical LCIS on MRI, there is need for
further studies on lobular neoplasia, which unlike other high-risk lesion
such as atypical ductal hyperplasia, is not routinely excised at all
institutions.
Published work on the incidence of upgrade following a diagnosis of
LN on core biopsy have typically included both mixed and pure LN
populations. To our knowledge, few papers have explored the patient
and LN lesion characteristics associated with upgrade rates of pure LN
[14,26]. Khoury et al. found that NME had a higher risk of upgrade than
enhancing masses but with borderline significance [14]. They found no
features associated with upgrade to malignancy, including age, clinical
indication, menopausal status or personal history of breast cancer.
Similarly, our study found no patient or lesion characteristics to indicate
upgrade on surgical excision. Therefore, it is imperative to be certain of
radiology-pathology correlation to ensure appropriate sampling, with
low threshold to recommend surgical excision if there is any
uncertainty.
Our study has limitations. It is a retrospective study from a single
institution. Not all LN lesions had surgical correlation, however, these
cases had clinical and imaging follow-up revealing no malignancies to
current date. MRI findings could theoretically be the result of the other
pathologies in the specimen besides LN, however, all cases were
reviewed by two breast fellowship trained radiologists in consensus and
correlated with the pathologic findings. Those cases where the breast
radiologists believed other pathologies could account for the MRI im
aging findings were excluded from analysis. The sample size was small,
therefore limiting further sub-analysis of findings, contributing to wide
confidence intervals. However, we believe that the investigation of pure
lobular neoplasia is a strength of our study.
In conclusion, the incidence of pure lobular neoplasia on MRI guided
biopsy is low, with comparatively low incidence of upgrade to malig
nancy in this study population. Pure LN is most often associated with
focal, heterogeneous non-mass enhancement with low T2 signal. In our
study, no cases of ALH on MRI were subsequently found to be malignant
on histopathology or imaging/clinical follow-up. No distinguishing
imaging or clinical features were present to indicate upgrade on surgical
excision. Further studies are needed to evaluate independent clinical
and radiological features of pure LN and likelihood of upgrade. At this
time, continued prudent radiologic-pathologic correlation with atten
tion to appropriate sampling and clinical risk factors is needed to
determine management.
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